Vacyte 450 & Valcyte 50 Mg/Ml 450. 50 mg/mL FC tablet. powder for oral solution
PDF Leaflet Revision Date: 31 July 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of CMV retinitis and prevention of CMV disease in at-risk transplant patients.
Dosage (summary)
900 mg valganciclovir (2 tablets) twice daily for 21 days for CMV retinitis; 900 mg once daily for prevention in transplant patients.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding; potential teratogenic effects.
Key Drug Interactions
- Zidovudine
- Didanosine
- Imipenem-cilastatin
Contraindications
- Hypersensitivity to valganciclovir or ganciclovir
Common side effects
- Neutropenia
- Anaemia
- Thrombocytopenia
- Diarrhoea
- Nausea
Counselling Points
- Take with food
- Use effective contraception
- Monitor blood counts regularly
Serious warnings
- Myelosuppression
- Potential teratogenic effects
- Risk of seizures
Important Disclaimer
The Vacyte 450 & Valcyte 50 Mg/Ml 450. 50 mg/mL FC tablet. powder for oral solution professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
